Loading…
Loading…
ONPPF (Oncopeptides AB (publ)) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
ONPPF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for ONPPF and 80,000+ other tickers.
See exactly how ONPPF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for ONPPF and 80,000+ other tickers.
Oncopeptides AB (publ) is a biotechnology company focused on developing pharmaceutical therapies to combat cancer. The firm's therapeutic innovations are intended for markets across the United States, Europe, and internationally. Its flagship product candidate, melflufen, is an advanced anti-cancer peptide drug conjugate specifically designed to treat adult patients afflicted with relapsed refractory multiple myeloma. Oncopeptides AB (publ) was founded in 2000 and is headquartered in Stockholm, Sweden.
Oncopeptides AB (publ) (ONPPF) Q4 2025 Sales/Trading Call Transcript
Oncopeptides AB (publ) (OTC:ONPPF) Q3 2025 Earnings Call November 5, 2025 3:00 AM EST Company Participants Sofia Heigis - Chief Executive Officer Henrik Bergentoft - Chief Financial Officer Conference Call Participants Richard Ramanius - Redeye AB, Research Division Presentation Operator Welcome to Oncopeptides' Third Quarter Earnings Call for 2025. [Operator Instructions] Now I will hand the conference over to CEO, Sofia Heigis; and CFO, Henrik Bergentoft.
STOCKHOLM, Aug. 27, 2021 /PRNewswire/ -- Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that data from the phase 3 OCEAN study has been accepted as an oral presentation at the upcoming 18th International Myeloma Workshop (IMW), and the abstract is now available online. More comprehensive data will be presented at the IMW-meeting in Vienna on September 11, at 10:00 (CET).
Oncopeptides AB (OTC: ONPPF) has some good news and some bad news from the updated results from Phase 3 OCEAN study of Pepaxto (melflufen) plus dexamethasone in patients with relapsed / refractory multiple myeloma who have received 2 – 4 prior lines of therapy. The good news is that while preparing the clinical study report and regulatory documents, Oncopeptides discovered that the independent review committee lacked access to all the information in the clinical database.